Relationship between JAK2V617F mutation, allele burden and coagulation function in Ph-negative myeloproliferative neoplasms

Figures & data

Table 1. The clinical characteristics of Ph-negative MPN patients.

MPNs	Case	Age/mean age (year)	Chromosome karyotype abnormal	Splenomegaly (%)	Vascular events
					Jak2 positive	Jak2 negative
PV	20	59.3	0	75	6	0
ET	95	57.2	0	47.3	15	6
PMF	18	60.7	0	77.8	2	0

Figure 1. The distribution of JAK2V617F mutation in different age groups.

Figure 2. The JAK2V617F mutation allele burden in ph-PMN patients was presented in (a). The JAK2V617F mutation allele burden between ET patients with vascular events and ET patients without vascular events were present in (b). The JAK2V617F mutation allele burden in the group age ≧65 were presented in (c). The JAK2V617F mutation allele burden in the group age <65 was presented in (d).

Figure 3. Distribution of MPNs according to the JAK2V617F mutation allele burden.

Table 2. Hematological characteristics of MPN patients in this cohort.

	ET			PMF
	Negative	Positive	p	Negative	Positive	p
Age (year), median (range)	56.5 (42.5–69)	62 (46.5–72)	0.114	59 (51–69)	64 (50–73)	0.990
RBC (10^9/L) , median (range)	4.14 (3.66–4.61)	4.63 (4.19–5.42)	0.000**	2.29 (1.50–3.04)	2.95 (2.12–4.05)	0.153
HB (g/L), median (range)	117.5 (101–130.7)	132 (115.5–148)	0.007*	70 (38–83)	91 (62–104)	0.140
WBC (10^9/L) , median (range)	8.26 (5.71–12.16)	10.74 (7.83–14.32)	0.008*	4.56 (1.48–5.67)	9.77 (3.40–23.07)	0.202
PLT (10^9/L) , median (range)	701 (578.5–917)	687 (553–895)	0.449	74 (34–727)	263 (76–904)	0.783
HCT (%), median (range)	0.37 (0.33–0.40)	0.40 (0.37–0.48)	0.002*	0.26 (0.14–0.34)	0.28 (.021–0.33)	0.552
MCV (fL), median (range)	90.30 (85.6–95.6)	89.15 (80.75–92.9)	0.263	88.40 (84.00–90.60)	90.90 (84.40–96.30)	0.442
MCH (pg), median (range)	29.00 (27.35–31.15)	28.95 ((26.65–30.38)	0.080	27.40 (25.30–29.50)	28.85 (26.33–30.90)	0.957
MCHC (g/L) , median (range)	325 (304–335)	319 (310–329)	0.626	308 (301–313)	317 (298–332)	0.231
PDW (%), median (range)	11.60 (10.60–13.45)	12.00 (11.50–13.40)	0.130	12.20 (10.90–13.10)	14.20 (11.20–16.85)	0.269

RBC: red blood cell, HB: hemoglobin, WBC: white blood cell, PLT: platelet, HCT: hematocrit, MCV: mean corpuscular volume, MCH: mean corpuscular hemoglobin, MCHC: mean corpuscular hemoglobin concentration, PDW: platelet distribution width.

Continuous variables were showed as median (range). *p < 0.05, **p < 0.001.

Figure 4. Correlation of JAK2V617F mutation allele burden with PLT counts. Regression parameters and significance values are indicated.

Table 3. Coagulation function of the patients in this cohort.

	ET			PMF
	Negative	Positive	p	Negative	Positive	p
PT-INR, median (range)	1.04 (0.95–1.14)	1.14 (1.03–1.21)	0.029*	1.00 (0.96–1.04)	1.13 (1.12–1.30)	0.002**
APTT(s), median (range)	33.50 (23.35–36.98)	34.50 (29.40–43.40)	0.398	33.80 (25.50–40.30)	39.90 (32.00–42.60)	0.386
TT(s), median (range)	17.80 (10.63–24.73)	19.50 (11.30–24.40)	0.756	16.60 (10.90–20.80)	18.10 (17.05–27.00)	0.329
FIB(g/L) , median (range)	2.81 (2.30–4.24)	2.34 (1.77–2.96)	0.217	3.73 (2.44–4.10)	2.34 (2.16–2.95)	0.059
D-D (ug/ml), median (range)	0.24 (0.19–0.38)	0.23 (0.10–0.59)	0.526	0.74 (0.60–3.41)	1.09 (0.46–4.17)	0.872
FDP (ug/ml), median (range)	1.41 (0.41–2.50)	2.05 (0.53–2.5)	0.389	1.80 (1.24–4.00)	2.80 (0.34–10.25)	0.885

PT-INR: prothrombin time-International normalized ratio, APTT: activated partial thromboplastin time, TT: thrombin time, FIB: plasma fibrinogen, FDP: fibrin degradation products.

Continuous variable were showed as Median (range). *p < 0.05, **p < 0.01

Figure 5 . Correlation of JAK2V617F mutation allele burden with APTT. Regression parameters and significance values are indicated.